EU Regulators Confirm Rare Vision Loss Risk for Novo’s Semaglutide

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include the “very rare” risk of non-arteritic anterior ischemic optic neuropathy.